Charles River Laboratories International, Inc. (CRL) Stock Price & Analysis
Charles River Laboratories International, Inc. (CRL) closed at USD 339.66 on Thursday, October 22, 2026, down 1.51% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 339.66; the Oct 22, 2026 session ranged USD 337.78–351.21 on volume of 2,662,266 shares. Market capitalization is —, with a 52-week range of USD 146.2–351.21 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRL.md
Key facts (CRL)
- Last four reported quarters (through Jun 27, 2026): revenue $4.00B, net income -$238M (-6.0% margin), free cash flow $371M (SEC filings).
- 2 of 80 tracked superinvestors hold CRL (13F, Q2 2026): 0 new, 2 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y +77.9% vs S&P 500 +14.9%; 5Y -19.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 2.98, revenue estimate $961M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CRL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.54B | $3.98B | $4.13B | $4.05B | $4.02B | $4.00B |
| Operating income | $590M | $651M | $617M | $227M | $25.2M | $90.1M |
| Net income | $391M | $486M | $475M | $22.2M | -$144M | -$238M |
| EPS (diluted) | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 | — |
| Free cash flow | $532M | $295M | $365M | $502M | $518M | $371M |
| Operating margin | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% | 2.3% |
| Net margin | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% | -6.0% |
| Revenue growth | +21.1% | +12.3% | +3.9% | -1.9% | -0.9% | — |
| Cash + short-term investments | $242M | — | — | $195M | $214M | — |
| Total debt | $2.66B | $2.71B | $2.65B | $2.24B | $2.14B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 27, 2026) (CRL)
P/E at fiscal year-ends: Dec 2024 429.2x, Dec 2023 25.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (CRL)
2 of 80 tracked investors hold CRL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| John Rogers | Ariel Investments | 3.41% | $342M | Added +4.3% |
| Bill Nygren | Oakmark Funds | 0.68% | $508M | Added +4.1% |
Analysts (CRL)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Morgan Stanley | Target raised | Overweight | $300 → $340 |
| 2026-09-28 | Jefferies | Target raised | Buy | $305 → $340 |
| 2026-09-25 | Deutsche Bank | Target raised | Buy | $300 → $320 |
| 2026-09-25 | TD Cowen | Target raised | Buy | $300 → $325 |
| 2026-09-25 | Evercore ISI Group | Target raised | Outperform | $320 → $330 |
| 2026-09-25 | RBC Capital | Target raised | Outperform | $282 → $322 |
| 2026-09-25 | Barclays | Target raised | Overweight | $300 → $330 |
| 2026-09-25 | Mizuho | Target raised | Neutral | $264 → $295 |
| 2026-09-25 | Baird | Target raised | Outperform | $291 → $334 |
| 2026-09-11 | Evercore ISI Group | Target raised | Outperform | $300 → $320 |
| 2026-08-10 | TD Cowen | Target raised | Buy | $235 → $300 |
| 2026-08-07 | Morgan Stanley | Target raised | Overweight | $260 → $300 |
Total return (dividends reinvested) (CRL)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +77.9% | -19.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +78.2% | -4.2% |
| Volatility (annualized) | 45.8% | 45.7% |
| Max drawdown | -33.9% (Jan 2026→May 2026) | -77.8% (Oct 2021→Apr 2025) |
CRL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.98 | $3.05 | -2.4% | $960.7M | 12 |
| Next quarter (ends Dec 2026) | $3.33 | $3.24 | +2.6% | $956.5M | 12 |
| Current fiscal year (ends Dec 2026) | $11.37 | $11.10 | +2.5% | $3.92B | 16 |
| Next fiscal year (ends Dec 2027) | $12.75 | $12.33 | +3.4% | $4.02B | 16 |
CRL options: expected move
Options price a move of about ±14.1% (±$47.80) by Nov 20, 2026, which includes earnings on Nov 4, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 62.0% | ±14.1% |
| Dec 18, 2026 | 56 | 53.5% | ±16.9% |
| Feb 19, 2027 | 119 | 51.6% | ±23.5% |
| May 21, 2027 | 210 | 50.6% | ±30.4% |
30-day implied volatility 62.2% vs 44.7% realized over the last 30 trading days. Put/call ratio (volume) 0.99. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:27 UTC)
| Price | USD 339.66 |
|---|---|
| Change | ▼ 1.51% (down) |
| Previous Close | USD 339.66 |
| Open | USD 339.66 |
| Day Range | USD 337.78 – 351.21 |
| 52-Week Range | USD 146.2 – 351.21 |
| Volume | 2,662,266 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (CRL)
Nexqual's technical model rates CRL "BUY" based on 5 bullish and 3 bearish signals across 127 daily candles, as of October 23, 2026 at 09:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 70.17 (overbought) |
| vs SMA50 | Above (USD 292.66) |
| MACD | 10.98 (positive) |
Earnings (CRL)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 2.98 |
| Revenue Estimate | $960.74M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 3.02 vs est 2.74 ▲ beat |
| 2026-03-31 | USD 2.06 vs est 1.95 ▲ beat |
| 2025-12-31 | USD 2.39 vs est 2.35 ▲ beat |
| 2025-09-30 | USD 2.43 vs est 2.34 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Financials & Fundamentals (CRL)
| Total Revenue | $4.00B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -2.70% |
| Gross Margin | +34.59% |
| Operating Margin | +15.11% |
| Profit Margin | -5.96% |
| ROE | -7.52% |
| Debt / Equity | 1.05 |
| Current Ratio | 1.35 |
| Total Cash | $192.02M |
| Total Debt | $3.03B |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Ownership (CRL)
| Insider Ownership | +0.47% |
|---|---|
| Institutional Ownership | +122.20% |
| Shares Outstanding | 48.17M |
| Float | 47.20M |
| Short % of Float | +6.97% |
Source: Nexqual, October 23, 2026 at 09:27 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RVTY | Revvity, Inc. | USD 157.36 | ▲ 0.48% |
| MEDP | Medpace Holdings, Inc. | USD 653.96 | ▼ 1.29% |
| ICLR | ICON plc | USD 185.43 | ▲ 0.1% |
| GH | Guardant Health, Inc. | USD 162.94 | ▼ 2.23% |
| QGEN | Qiagen N.V. | USD 50.22 | ▲ 0.44% |
| LH | Labcorp Holdings Inc. | USD 329.93 | ▲ 1.91% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt